A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine

European Journal of Haematology

Volumn 93, Issue 5, 2014, Pages 439-445

  Svensson, Tobias ^a   Chowdhury, Onima ^b   Garelius, Hege ^c   Lorenz, Fryderyk ^d   Saft, Leonie ^e   Jacobsen, Sten Eirik ^b   Hellström Lindberg, Eva ^e   Cherif, Honar ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Azacitidine; Eltrombopag; Myelodysplastic syndrome; Thrombocytopenia; Thrombopoietin receptor

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; AZACITIDINE; BILIRUBIN; ELTROMBOPAG; ANTINEOPLASTIC AGENT; BENZOIC ACID DERIVATIVE; HYDRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; THROMBOPOIETIN RECEPTOR;

ADULT; ADVERSE DRUG REACTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLURRED VISION; BRONCHITIS; CANDIDIASIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE COURSE; DOSE CALCULATION; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ERYSIPELAS; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FLOW CYTOMETRY; FOLLICULITIS; HEADACHE; HEMATOPOIETIC STEM CELL; HIGH RISK PATIENT; HUMAN; INFECTIOUS COMPLICATION; INJECTION SITE REACTION; LEG EDEMA; LEUKEMIA REMISSION; LOSS OF APPETITE; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MYALGIA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NAUSEA; PARONYCHIA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; PURPURA; REMISSION; STAPHYLOCOCCAL BACTEREMIA; THORAX PAIN; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TOOTH INFECTION; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT INFECTION; URTICARIA; VERTIGO; AGONISTS; CELL CYCLE; CLINICAL TRIAL; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; ISCHEMIC ATTACK, TRANSIENT; METABOLISM; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; PILOT STUDY; THROMBOCYTE; VENOUS THROMBOSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AZACITIDINE; BENZOATES; BLOOD PLATELETS; CELL CYCLE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; HYDRAZINES; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PILOT PROJECTS; PLATELET COUNT; PYRAZOLES; RECEPTORS, THROMBOPOIETIN; REMISSION INDUCTION; THROMBOCYTOPENIA; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 84911978389     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12383     Document Type: Article

References (21)

1. List AF. New approaches to the treatment of myelodysplasia. Oncologist 2002;7:39-49.
2. Warlick ED, Smith BD. Myelodysplastic syndromes: review of pathophysiology and current novel treatment approaches. Curr Cancer Drug Targets 2007;7:541-58.
3. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
4. Sekeres MA, Schoonen WM, Kantarjian H, List A, Fryzek J, Paquette R, Maciejewski JP. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst 2008;100:1542-51.
5. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429-40.
6. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223-32.
7. Gurion R, Vidal L, Gafter-Gvili A, Belnik Y, Yeshurun M, Raanani P, Shpilberg O. 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome-a systematic review and meta-analysis. Haematologica 2010;95:303-10.
8. Kantarjian H, Giles F, List A, Lyons R, Sekeres MA, Pierce S, Deuson R, Leveque J. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer 2007;109:1705-14.
9. Kao JM, McMillan A, Greenberg PL. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol 2008;83:765-70.
10. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357:2237-47.
11. Erickson-Miller CL, Kirchner J, Aivado M, May R, Payne P, Chadderton A. Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag. Leuk Res 2010;34:1224-31.
12. Will B, Kawahara M, Luciano JP, Bruns I, Parekh S, Erickson-Miller CL, Aivado MA, Verma A, Steidl U. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood 2009;114:3899-908.
13. Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS, Verma A, Steidl U. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood 2012;120:386-94.
14. Sugita M, Kalota A, Gewirtz AM, Carroll M. Eltrombopag inhibition of acute myeloid leukemia cell survival does not depend on c-Mpl expression. Leukemia 2013;27:1207-10.
15. Drachman JG. Role of thrombopoietin in hematopoietic stem cell and progenitor regulation. Curr Opin Hematol 2000;7:183-90.
16. Qian H, Buza-Vidas N, Hyland CD, Jensen CT, Antonchuk J, Mansson R, Thoren LA, Ekblom M, Alexander WS, Jacobsen SE. Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. Cell Stem Cell 2007;1:671-84.
17. Ballmaier M, Germeshausen M. Advances in the understanding of congenital amegakaryocytic thrombocytopenia. Br J Haematol 2009;146:3-16.
18. Tehranchi R, Woll PS, Anderson K, et al. Persistent malignant stem cells in del(5q) myelodysplasia in remission. N Engl J Med 2010;363:1025-37.
19. Kantarjian HM, Mufti GJ, Fenaux P, et al. Treatment with the thrombopoietin (TPO)-receptor agonist romiplostim in thrombocytopenic patients (Pts) with low or intermediate-1 (int-1) risk myelodysplastic syndrome (MDS): follow-up AML and survival results of a randomized, double-blind, placebo (PBO)-controlled study. ASH Annu Meet Abstr 2012;120:421.
20. Rusnak DW, Rudolph SK, Safavi A, Erickson-Miller CL. Eltrombopag, but not romiplostim or thrombopoietin, inhibits growth of thrombopoietin receptor positive and negative human leukemia cell lines. ASH Annu Meet Abstr 2012;120:4726.
21. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, Larson RA. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia group B. J Clin Oncol 2006;24:3895-903.